Corporate Overview

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Our unique platform allows us to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases, giving us the potential to positively affect millions of patients who are underserved by current therapeutic alternatives.

The core technology behind our platform was developed at and licensed from the Massachusetts Institute of Technology, Harvard University, Whitehead Institute for Biomedical Research and Massachusetts General Hospital. Our human-driven immunoprofiling platform enables us to extensively interrogate the human immune microenvironment to identify and validate potential drug candidates.

Our platform enables us to study rare immune cells from human patients at high resolution and measure drug effects in a patient-specific, disease-specific manner. Harnessing The Power of Human™, our platform provides a basis for developing best-in-class product candidates from a fundamental understanding of how immunotherapies work in each patient. Our vision then is to use this human-derived knowledge to better predict which antibody drug candidates are most likely to be effective in a targeted group of patients, with the goals of reducing side effects and accelerating the drug discovery process. Our discoveries will not only be valuable for the development of therapeutic antibodies but also as potential diagnostic products.

Initially, we are building a pipeline of immunomodulators that target checkpoint proteins, which the body use to prevent runaway immune responses that can prove debilitating or even deadly. Our near term goals include preclinical testing for our internal pipeline programs in our human-driven platform, as well as in other preclinical models.

We are leveraging the breadth of our technology through strategic collaborations. To date, we have engaged in several proof-of-concept collaborations with several leading pharmaceutical companies. Through them, our technology has been validated in a commercial setting, and a number of applications have been demonstrated.

In July 2014, we raised $21.5 million through a private placement offering and began public trading on the OTC Markets (OTCQB) with the ticker ENUM.